A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
UNLABELLED: Our goal was to design and manufacture a kit under good manufacturing practices (GMP) for the preparation of (111)In-DTPA-hEGF Injection, a novel targeted radiotherapeutic agent for advanced epidermal growth factor receptor (EGFR)-positive breast cancer. METHODS: Human EGF (hEGF) was de...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2004
|
| _version_ | 1826277372857417728 |
|---|---|
| author | Reilly, R Scollard, D Wang, J Mondal, H Chen, P Henderson, L Bowen, B Vallis, K |
| author_facet | Reilly, R Scollard, D Wang, J Mondal, H Chen, P Henderson, L Bowen, B Vallis, K |
| author_sort | Reilly, R |
| collection | OXFORD |
| description | UNLABELLED: Our goal was to design and manufacture a kit under good manufacturing practices (GMP) for the preparation of (111)In-DTPA-hEGF Injection, a novel targeted radiotherapeutic agent for advanced epidermal growth factor receptor (EGFR)-positive breast cancer. METHODS: Human EGF (hEGF) was derivatized with diethylenetriaminepentaacetic acid (DTPA) and then purified by size-exclusion chromatography and ultrafiltration. Kits were prepared by dispensing 0.25 mg (1 mL) of DTPA-hEGF in 1 mol/L sodium acetate buffer [pH 6.0] into single-dose glass vials. Raw materials were pharmacopoieal or reagent grade according to the American Chemical Society and were tested for identity and purity. Kits were tested for protein concentration, purity and homogeneity (sodium dodecyl sulfate polyacrylamide gel electrophoresis and size-exclusion high-performance liquid chromatography), pH, clarity and color, volume, DTPA substitution, labeling efficiency, receptor binding to MDA-MB-468 human breast cancer cells, and sterility and apyrogenicity. (111)In-DTPA-hEGF Injection was tested for pH, radionuclidic and radiochemical purity, clarity and color, and sterility and apyrogenicity. RESULTS: Four lots of kits and 8 lots of (111)In-DTPA-hEGF Injection passed all quality specifications. The labeling efficiency was 94%-99% with 115-773 MBq (111)In chloride added to a single kit. (111)In-DTPA-hEGF exhibited preserved receptor binding against MDA-MB-468 cells (affinity constant [K(a)], 0.9-1.1 x 10(7) L/mol; maximum number of binding sites per cell [B(max)], 1.1-2.2 x 10(6) sites per cell). In addition, labeling of aliquots of the kit suggested that a single vial could be labeled with up to 3,083 MBq (111)In while maintaining a radiochemical purity of >90%. Kits were stable for >90 d and (111)In-DTPA-hEGF Injection was stable for >24 h stored at 4 degrees C. CONCLUSION: The kit formulation is suitable for preparing (111)In-DTPA-hEGF Injection for a phase I clinical trial in patients with advanced EGFR-positive breast cancer. Establishment of the GMP processes for (111)In-DTPA-hEGF Injection provides a useful example of manufacturing biotechnology-based investigational radiopharmaceuticals in an academic environment for early phase I clinical trials. |
| first_indexed | 2024-03-06T23:27:56Z |
| format | Journal article |
| id | oxford-uuid:6b080890-04a5-49b0-bd6d-750e528c0f35 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:27:56Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:6b080890-04a5-49b0-bd6d-750e528c0f352022-03-26T19:01:09ZA kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6b080890-04a5-49b0-bd6d-750e528c0f35EnglishSymplectic Elements at Oxford2004Reilly, RScollard, DWang, JMondal, HChen, PHenderson, LBowen, BVallis, K UNLABELLED: Our goal was to design and manufacture a kit under good manufacturing practices (GMP) for the preparation of (111)In-DTPA-hEGF Injection, a novel targeted radiotherapeutic agent for advanced epidermal growth factor receptor (EGFR)-positive breast cancer. METHODS: Human EGF (hEGF) was derivatized with diethylenetriaminepentaacetic acid (DTPA) and then purified by size-exclusion chromatography and ultrafiltration. Kits were prepared by dispensing 0.25 mg (1 mL) of DTPA-hEGF in 1 mol/L sodium acetate buffer [pH 6.0] into single-dose glass vials. Raw materials were pharmacopoieal or reagent grade according to the American Chemical Society and were tested for identity and purity. Kits were tested for protein concentration, purity and homogeneity (sodium dodecyl sulfate polyacrylamide gel electrophoresis and size-exclusion high-performance liquid chromatography), pH, clarity and color, volume, DTPA substitution, labeling efficiency, receptor binding to MDA-MB-468 human breast cancer cells, and sterility and apyrogenicity. (111)In-DTPA-hEGF Injection was tested for pH, radionuclidic and radiochemical purity, clarity and color, and sterility and apyrogenicity. RESULTS: Four lots of kits and 8 lots of (111)In-DTPA-hEGF Injection passed all quality specifications. The labeling efficiency was 94%-99% with 115-773 MBq (111)In chloride added to a single kit. (111)In-DTPA-hEGF exhibited preserved receptor binding against MDA-MB-468 cells (affinity constant [K(a)], 0.9-1.1 x 10(7) L/mol; maximum number of binding sites per cell [B(max)], 1.1-2.2 x 10(6) sites per cell). In addition, labeling of aliquots of the kit suggested that a single vial could be labeled with up to 3,083 MBq (111)In while maintaining a radiochemical purity of >90%. Kits were stable for >90 d and (111)In-DTPA-hEGF Injection was stable for >24 h stored at 4 degrees C. CONCLUSION: The kit formulation is suitable for preparing (111)In-DTPA-hEGF Injection for a phase I clinical trial in patients with advanced EGFR-positive breast cancer. Establishment of the GMP processes for (111)In-DTPA-hEGF Injection provides a useful example of manufacturing biotechnology-based investigational radiopharmaceuticals in an academic environment for early phase I clinical trials. |
| spellingShingle | Reilly, R Scollard, D Wang, J Mondal, H Chen, P Henderson, L Bowen, B Vallis, K A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. |
| title | A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. |
| title_full | A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. |
| title_fullStr | A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. |
| title_full_unstemmed | A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. |
| title_short | A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. |
| title_sort | kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111in for radiotherapeutic applications |
| work_keys_str_mv | AT reillyr akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT scollardd akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT wangj akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT mondalh akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT chenp akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT hendersonl akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT bowenb akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT vallisk akitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT reillyr kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT scollardd kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT wangj kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT mondalh kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT chenp kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT hendersonl kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT bowenb kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications AT vallisk kitformulatedundergoodmanufacturingpracticesforlabelinghumanepidermalgrowthfactorwith111inforradiotherapeuticapplications |